Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ffect profile, mean that, if approved, satraplatin will represent an important new therapy option for patients with advanced prostate cancer whose prior chemotherapy has failed."

The relative risk of disease progression favored satraplatin for all pre- specified patient subsets, including prior Taxotere use, geographies, and the presence or absence of pain. For each of the 20 subsets presented today, the reduction in relative risk of disease progression ranged from 26% to 46%, corresponding to hazard ratios between 0.74 and 0.54.

Disease progression in the SPARC trial was defined as the first occurrence of any of several types of progression, including radiologic tumor progression (RECIST for soft tissue lesions or two or more new lesions on a bone scan); skeletal-related events (including a bone fracture, bone surgery or initiation of bisphosphonates); symptomatic progression (pain, weight loss, worsening of performance status); or death from any cause. Approximately 37% of patients in the trial progressed by pain and approximately 36% progressed on radiologic evidence. The hazard ratio for PFS for the subset of patients with pain progression or death was 0.64 (95% CI: 0.51-0.79, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients with radiologic progression or death was 0.64 (95% CI: 0.51-0.81, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients who progressed in ways other than radiologic or pain progression was 0.86 (95% CI: 0.63-1.17, p > 0.05).

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. As previously communicated, the interim analysis for overall survival conducted in June 2006 showed a trend, although not statistically si
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/28/2015)...   Heska Corporation  (NASDAQ:  HSKA -  News ; ... veterinary diagnostic and other specialty veterinary products , ... i ® Immunodiagnostic Analyzer. Element i performs ... concerns, including thyroid disorders, Cushing,s disease and Addison,s ... top analyzer that delivers rapid immunoassay testing, including ...
(Date:7/28/2015)... Scripts Holding Company (Nasdaq: ESRX ) announced 2015 ... of $600.1 million, or $0.88 per diluted share.  Adjusted ... were $1.44 for the second quarter. 1  ... are validating the need for size and scale," said ... matters most is how that size and scale is ...
(Date:7/28/2015)... July 28, 2015 /PRNewswire-USNewswire/ -- ... and doctor shopping after a 2012 law required providers ... addictive medications is yet more evidence that Californians need ... Since Kentucky,s prescription drug ... shopping" declined by 52 percent; opioid prescriptions to doctor-shopping ...
Breaking Medicine Technology:Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 2Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25Study Shows Requiring Prescription Drug Database Use Before Prescribing Powerful, Addictive Medications Critical In Ending Growing Epidemic, says Consumer Watchdog 2
... 7, 2011 Boston Scientific Corporation (NYSE: BSX ... the Federal Circuit affirmed the decision of the U.S. District ... in a suit involving Johnson & Johnson to be invalid. ... Johnson alleged that Boston Scientific,s PROMUS® Everolimus-Eluting Coronary Stent System ...
... Healthpoint Biotherapeutics today announced that Travis E. Baugh, ... Executive Vice President, Strategic and Commercial Development, will ... products and its R&D pipeline at two upcoming ... 2:30 pm(EDT) on Thursday, June 9, 2011 during ...
Cached Medicine Technology:Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents 2Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents 3Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences 2
(Date:7/28/2015)... ... 2015 , ... The Denver Foundation and Blair-Caldwell African American ... a photographic and narrative exploration of African American giving, which runs August 1-31 ... Denver is one of only ten cities to host “The Soul of Philanthropy ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... 1 in 68 children currently affected with the disorder. For these families, identifying ... road to recovery is extremely daunting. That’s where Talk About Curing Autism (TACA), ...
(Date:7/28/2015)... ... July 16, 2015 (PRWEB) July 28, 2015 , ... ... providing Health insurance quotes to its clients, recently announced the launch of Commercial, ... best suits their specific needs. , Liability automobile insurance policies are one ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... La Mirada, CA (PRWEB) , ... July 28, 2015 , ... ... XC, a collagen-filling injectable that returns skin to a smooth state, and reduces the ... XC is the “first and only FDA-approved injectable gel to instantly add volume to ...
Breaking Medicine News(10 mins):Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3
... 7 Diabetes America, the premier network,of diabetes care ... that five of its physicians have been recognized by ... to their patients. Dr. Wendy Hawkins M.D., Dr. Damon,Weddington ... and Dr. Eddie,Tejeda M.D. were all honored in Houston ...
... Face Recognition Engines, VILNIUS, Lithuania, Nov. ... identification technologies, today,announced the availability of the ... MegaMatcher face identification engines. Like the,Smartcard Finger-Match ... verifies biometric facial information on a smartcard, ...
... Nov. 7 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. (TSX: DND) today announced ... ended September 30, 2007. Q3 2007 Summary --------------- ... agreement with ProEthic Pharmaceuticals under ... to market, sell and distribute CIP-FENOFIBRATE (approved and ...
... factor for prostate, breast and colon cancer, but recent ... fat cells also plays an important role in cancer. ... for the first time, a genome-wide analysis of how ... on various genes related to obesity. , ...
... to Significantly Grow Lutein Usage Globally, LAS ... Kemin,Health, L.C. (Kemin), creator of FloraGLO(R) lutein the ... the premium supplier of,vitamins, carotenoids, and nutraceuticals, announced ... usage and the eye health,supplement category worldwide. ...
... affect both domestic and imported items, agency says , , ... U.S. outbreaks of illness linked to domestic and imported ... ask Congress to give it the authority to force ... officials announced Tuesday. , Currently, the agency can only ...
Cached Medicine News:Health News:Diabetes America Physicians Achieve Industry Recognition for Quality Patient Care 2Health News:Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems 2Health News:Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems 3Health News:Cipher reports third quarter fiscal 2007 results 2Health News:Cipher reports third quarter fiscal 2007 results 3Health News:Cipher reports third quarter fiscal 2007 results 4Health News:Cipher reports third quarter fiscal 2007 results 5Health News:Cipher reports third quarter fiscal 2007 results 6Health News:Cipher reports third quarter fiscal 2007 results 7Health News:Cipher reports third quarter fiscal 2007 results 8Health News:Cipher reports third quarter fiscal 2007 results 9Health News:Cipher reports third quarter fiscal 2007 results 10Health News:Cipher reports third quarter fiscal 2007 results 11Health News:Cipher reports third quarter fiscal 2007 results 12Health News:Cipher reports third quarter fiscal 2007 results 13Health News:Cipher reports third quarter fiscal 2007 results 14Health News:Cipher reports third quarter fiscal 2007 results 15Health News:Cipher reports third quarter fiscal 2007 results 16Health News:Cipher reports third quarter fiscal 2007 results 17Health News:Cipher reports third quarter fiscal 2007 results 18Health News:Cipher reports third quarter fiscal 2007 results 19Health News:Cipher reports third quarter fiscal 2007 results 20Health News:Researchers chart the genetic mechanisms behind the genesis of fat cells 2Health News:Kemin and DSM Forge Long-Term Strategic Alliance 2Health News:Kemin and DSM Forge Long-Term Strategic Alliance 3Health News:FDA Seeks Food Recall Authority 2Health News:FDA Seeks Food Recall Authority 3
Used to remove wrinkles from sections and for reorientating embedded tissue....
Liquichek Blood Gas Plus CO-Oximeter Control (Radiometer) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximeter (Radiometer) ...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Medicine Products: